Things appear to be going from bad to worse at Teva, which is giving the strong impression of being in meltdown. One can only hope that the recent Q2 results, which featured an eye-watering $6.1bn write-down of the company’s recently-acquired Actavis generics assets, mark...
Hikma’s strategy in the balance as it considers strategic options
Hikma’s FY 2012 results, which were out yesterday, made no direct mention of the company’s announcement on March 1st that it might sell its injectables business, but nevertheless provided considerable food for thought about Hikma’s future strategic direction. Analyst interest focused mainly on the...
The end is nigh: Teva admits that sales have peaked in the US
On Teva’s recent Q3 results conference call, the company’s US head, Bill Marth, admitted for the first time that the US generics market is now ex-growth, at least as far as Teva is concerned. Given that the company’s North American generic sales were down...
Q2 figures show the US majors having a hard time in Europe
Teva, Watson and Mylan all reported their Q2 figures last week but while the companies experienced differing fortunes in the US (strong growth for Mylan and Watson, a sharp decline for Teva), they were united in experiencing a mediocre quarter in Europe. Mylan did...